Combined intravitreal bevacizumab and triamcinolone acetonide injection for idiopathic neuroretinitis.
OBJECTIVE
To present a case with idiopathic neuroretinitis that was treated with combined intravitreal bevacizumab and triamcinolone.


METHODS
Case report.


METHODS
Interventional case report.


RESULTS
A 31-year-old man presented with a visual acuity of 3/10 and afferent pupillary defect in the right eye. Ophthalmologic examination disclosed papillitis and macular edema. Neurology consultation with cranial computerized tomography scan revealed no abnormality. The patient was injected with bevacizumab and triamcinolone intravitreally. One week later, the vision increased to 10/10, macular edema disappeared. One month later, optic disc edema disappeared.


CONCLUSIONS
Intravitreal injection of bevacizumab and triamcinolone effectively treated idiopathic neuroretinitis.
Cakir
Mehmet
M
Beyoğlu Eye Training and Research Hospital, Istanbul, Turkey. drmcakir@hotmail.com
Cekiç
Osman
O
Bozkurt
Ercüment
E
Pekel
Gökhan
G
Yazici
Ahmet T
AT
Yilmaz
Omer F
OF
D000328:Adult; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D004359:Drug Therapy, Combination; D005451:Fluorescein Angiography; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D007267:Injections; D008297:Male; D010211:Papilledema / Q000188:drug therapy; D012173:Retinitis / Q000188:drug therapy*; D041623:Tomography, Optical Coherence; D014222:Triamcinolone Acetonide / Q000627:therapeutic use*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D005938:Glucocorticoids; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D014222:Triamcinolone Acetonide